Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > primary biliary cholangitis therapeutics market
Get a free sample of Primary Biliary Cholangitis Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Primary Biliary Cholangitis Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture advanced primary biliary cholangitis therapeutics products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for primary biliary cholangitis therapeutics.
Prominent players operating in the market are as mentioned below:
Abbott Laboratories, Arlak Biotech Pvt. Ltd, Cadila Pharmaceuticals, Drag Pharma, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Ipsen, Leeford Healthcare Limited, Lupin, Sun Pharmaceuticals Ltd., Viatris, Inc. (Mylan N.V.), and Vivaldis.
North America primary biliary cholangitis (PBC) therapeutics market held 45.2% revenue share in 2023 due to the high prevalence of PBC and rigorous regulatory standards set by the U.S. Food and Drug Administration (FDA) ensure the safety, efficacy, and quality.
The human segment in the primary biliary cholangitis (PBC) therapeutics market held 88.2% revenue share in 2023 led by the rising prevalence of primary biliary cholangitis in women and well-developed healthcare infrastructure for effective treatment delivery.
Global primary biliary cholangitis (PBC) therapeutics industry was valued at USD 677.2 million in 2023 and is anticipated to register 7.1% CAGR between 2024 and 2032 due to the rising prevalence of primary biliary cholangitis and increasing advancements in diagnostic technologies.